Over the past 12 months, 0 insiders at Global Blood Therapeutics, Inc. filed 0 open-market SEC Form 4 transactions on GBT: 0 purchases worth $0 and 0 sales worth $0. Insiders have been mixed over this period. The most recent filing was on .
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 1, 22 | Jeffrey S FarrowChief Financial Officer | SELL | 31.4K | $68.00 | $2.1M |
| Aug 18, 22 | Nazila HabibizadSee Remarks | SELL | 4.7K | $67.19 | $314K |
| Jun 21, 22 | Philip A. PizzoDirector | SELL | 1.3K | $27.25 | $34K |
| Jun 21, 22 | Dawn SvoronosDirector | SELL | 1.9K | $27.24 | $52K |
| Sep 9, 21 | Scott W MorrisonDirector | SELL | 4.8K | $30.21 | $145K |
Over the past 12 months, insiders at Global Blood Therapeutics, Inc. filed 0 open-market purchases worth $0 and 0 sales worth $0 on GBT, which makes them mixed over the period. The most recent Form 4 was filed on .
0 different insiders at Global Blood Therapeutics, Inc. filed open-market SEC Form 4 transactions on GBT over the last 12 months.
InsiderTape plots every GBT insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Global Blood Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →